مقاله انگلیسی رایگان در مورد مقاومت دارویی سرطانهای سر و گردن – الزویر ۲۰۲۰

elsevier

 

مشخصات مقاله
ترجمه عنوان مقاله RNA های غیر کد کننده در مقاومت دارویی سرطانهای سر و گردن: یک مقاله مروری
عنوان انگلیسی مقاله Non-coding RNAs in drug resistance of head and neck cancers: A review
انتشار مقاله سال ۲۰۲۰
تعداد صفحات مقاله انگلیسی ۱۳ صفحه
هزینه دانلود مقاله انگلیسی رایگان میباشد.
پایگاه داده نشریه الزویر
نوع نگارش مقاله
مقاله مروری (Review Article)
مقاله بیس این مقاله بیس نمیباشد
نمایه (index) Scopus – Master Journals List – JCR
نوع مقاله ISI
فرمت مقاله انگلیسی  PDF
ایمپکت فاکتور(IF)
۳٫۸۲۹ در سال ۲۰۱۹
شاخص H_index ۷۸ در سال ۲۰۲۰
شاخص SJR ۰٫۹۳۱ در سال ۲۰۱۹
شناسه ISSN ۰۷۵۳-۳۳۲۲
شاخص Quartile (چارک) Q2 در سال ۲۰۱۹
مدل مفهومی ندارد
پرسشنامه ندارد
متغیر ندارد
رفرنس دارد
رشته های مرتبط پزشکی، داروسازی
گرایش های مرتبط ژنتیک پزشکی، پزشکی مولکولی، داروسازی بالینی
نوع ارائه مقاله
ژورنال
مجله  زیست پزشکی و داروسازی – Biomedicine & Pharmacotherapy
دانشگاه  Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical University, Taiyuan, 030001, Shanxi, PR China
کلمات کلیدی سرطان سر و گردن، RNA غیر کد کننده، میکرو RNA، RNA غیر کد کننده طولانی، RNA حلقوی، مقاومت دارویی، مقاومت شیمیایی
کلمات کلیدی انگلیسی Head and neck cancer، Non-coding RNA، MicroRNA، Long non-coding RNA، Circular RNA، Drug resistance، Chemo resistance
شناسه دیجیتال – doi
https://doi.org/10.1016/j.biopha.2020.110231
کد محصول E14960
وضعیت ترجمه مقاله  ترجمه آماده این مقاله موجود نمیباشد. میتوانید از طریق دکمه پایین سفارش دهید.
دانلود رایگان مقاله دانلود رایگان مقاله انگلیسی
سفارش ترجمه این مقاله سفارش ترجمه این مقاله

 

فهرست مطالب مقاله:
Abstract
Graphical abstract
۱٫ Background
۲٫ Current known mechanisms of HNC drug resistance
۳٫ MiRNAs in HNC cell drug resistance
۴٫ Long non-coding RNAs in HNC cell drug resistance
۵٫ CircRNAs in HNC cell drug resistance
۶٫ Expression of non-coding RNAs is associated with overall survival in HNC
۷٫ Future perspectives
۸٫ Conclusions
Authors’ contributions
Funding
Consent for publication
Availability of data and materials
Declaration of Competing Interest
References

بخشی از متن مقاله:
Abstract

Head and neck cancer (HNC), which includes epithelial malignancies of the upper aerodigestive tract (oral cavity, oropharynx, pharynx, hypopharynx, larynx, and thyroid), are slowly but consistently increasing, while the overall survival rate remains unsatisfactory. Because of the multifunctional anatomical intricacies of the head and neck, disease progression and therapy-related side effects often severely affect the patient’s appearance and self-image, as well as their ability to breathe, speak, and swallow. Patients with HNC require a multidisciplinary approach involving surgery, radiation therapy, and chemotherapeutics. Chemotherapy is an important part of the comprehensive treatment of tumors, especially advanced HNC, but drug resistance is the main cause of poor clinical efficacy. The most important determinant of this phenomenon is still largely unknown. Recent studies have shown that non-coding RNAs have a crucial role in HNC drug resistance. In addition, they can serve as biomarkers in the diagnosis, treatment, and prognosis of HNCs. In this review, we summarize the relationship between non-coding RNAs and drug resistance of HNC, and discuss their potential clinical application in overcoming HNC chemoresistance.

Background

Head and neck cancer (HNC) is a major global health problem. More than 890,000 new cases of HNC and approximately 450,000 HNC-related deaths occur every year [1,2]. The majority of cases are HN squamous cell carcinoma (HNSCC) [3], involving the stratified epithelium of the oral cavity, pharynx, and larynx, with an overall 5-year survival rate of only 40%–۵۰% [۳]. Most HNC is closely related to tobacco and alcohol use [1–۳]. Patients with HNC might have symptoms including hoarseness, dysphagia, pain, neck mass, and ulcers, which require a multidisciplinary approach involving surgery, radiation therapy, and chemotherapy [4]. Although the treatment is effective for early and locally advanced disease, the prognosis of recurrent and metastatic disease remains poor [5]. Clinically, more than 65% of patients are diagnosed with advanced disease because of the lack of early diagnosis [6]. However, both radiotherapy and surgery reduce patients’ quality of life at this stage [2]. Radiotherapy usually produces obvious side effects, while surgery can significantly affect the normal physiological structure and function of patients [2,7]. Additionally, targeted therapy for HNC has been incorporated into clinical treatment guidelines, but its clinical response and long-term effect are limited, and high costs are associated with this treatment [8]. In recent years, chemical treatment of advanced HNC has been increasingly recognized [9]. In early phase II clinical trials in patients with advanced HNSCC, significant single-agent response rates were up to 30% [5,10].

ارسال دیدگاه

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *